Research development of a new GnRH antagonist (Elagolix) for the treatment of endometriosis: a review of the literature

[11] Plotti F(2015)Pain control and quality of life after laparoscopic en-block resection of deep infiltrating endometriosis (DIE) vs. incomplete surgical treatment with or without GnRHa administration after surgery Arch Gynecol Obstet 291 363-207

[12] Mabrouk M(2016)Can postoperative GnRH agonist treatment prevent endometriosis recurrence? A meta-analysis Arch Gynecol Obstet 294 201-37

[13] Elmakky A(2016)Anti-Mullerian hormone trend evaluation after laparoscopic surgery of monolateral endometrioma using a new dual wavelengths laser system (DWLS) for hemostasis Gynecol Endocrinol 32 34-2457

[14] Caramelli E(2008)Diagnostic value of transvaginal terderness guided ultrasonography for the prediction of location of deep endometriosis Hum Reprod 23 2452-408

[15] Juhaza-Boss I(2015)Dienogest. A possible conservative approach in bladder endometriosis. Results of a pilot study Gynecol Endocrinol 31 406-28

[16] Fischer C(2015)Progestins for symptomatic endometriosis: results of clinical studies Curr Drug Ther 10 9194.13-588

[17] Lattrich C(2015)Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain Womens Health (Lond) 11 19-551

[18] Mereu L(2016)Overview of elagolix for the treatment of endometriosis Expert Opin Drug Metab Toxic 12 581-371

[19] Florio P(2009)Suppression of gonadotropin and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix J Clin Endocrinol Metab 94 545-115

[20] Carri G(2014)Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study Reprod Sci 21 363-e269

[11] Plotti F(2015)Pain control and quality of life after laparoscopic en-block resection of deep infiltrating endometriosis (DIE) vs. incomplete surgical treatment with or without GnRHa administration after surgery Arch Gynecol Obstet 291 363-207

[12] Mabrouk M(2016)Can postoperative GnRH agonist treatment prevent endometriosis recurrence? A meta-analysis Arch Gynecol Obstet 294 201-37

[13] Elmakky A(2016)Anti-Mullerian hormone trend evaluation after laparoscopic surgery of monolateral endometrioma using a new dual wavelengths laser system (DWLS) for hemostasis Gynecol Endocrinol 32 34-2457

[14] Caramelli E(2008)Diagnostic value of transvaginal terderness guided ultrasonography for the prediction of location of deep endometriosis Hum Reprod 23 2452-408

[15] Juhaza-Boss I(2015)Dienogest. A possible conservative approach in bladder endometriosis. Results of a pilot study Gynecol Endocrinol 31 406-28

[16] Fischer C(2015)Progestins for symptomatic endometriosis: results of clinical studies Curr Drug Ther 10 9194.13-588

[17] Lattrich C(2015)Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain Womens Health (Lond) 11 19-551

[18] Mereu L(2016)Overview of elagolix for the treatment of endometriosis Expert Opin Drug Metab Toxic 12 581-371

[19] Florio P(2009)Suppression of gonadotropin and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix J Clin Endocrinol Metab 94 545-115

[20] Carri G(2014)Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study Reprod Sci 21 363-e269